henan lingrui pharmaceutical plans to acquire Silver Valley Pharmaceuticals for 0.782 billion. Traditional Chinese medicine patch and plaster leading the cross-border pharmaceutical market | Quick reading announcement

①Henan Lingrui Pharmaceutical intends to acquire all the equity of Silver Valley Pharmaceutical for 0.782 billion yuan, entering the market of innovative drugs in chemical medicine. ②According to Mononucleosis Medical Data, Silver Valley Pharmaceutical's sales in 2023 exceeded 0.4 billion yuan, with the top-selling product being Jin'erli, accounting for about 70% of the company's total revenue, and the growth rate of Class 1 new drug Biti Cong quickly. ③If the acquisition of Silver Valley Pharmaceutical proceeds smoothly, the company's previously set stock-based incentive unlocking target may be difficult to achieve or significantly reduced.

cls.cnDec 4 10:07 ET

Bank of Shanghai Interbank Association: As of the end of October, the Shanghai Silver Tax Platform has cumulatively issued loans of 48.315 billion yuan, with inclusive small and micro loans as the focus of the fourth quarter.

The data from the Bank of Shanghai Interbank Association shows that as of the end of October 2024, there are 61 cooperating banks involved in silver-tax interaction. The total number of registered companies on the silver-tax platform is over 0.2357 million, with a total credit limit of 128.178 billion yuan and cumulative loan disbursements of 48.315 billion yuan.

cls.cnDec 4 09:38 ET

The transfer price for the shareholders of Feivate has been initially set, with a discount of 14.68% compared to the market price, and 8 institutional investors are participating in the acquisition.

① Investment banking professionals at institutions indicate that the shareholding method of inquiry transfer is an innovation in the design of the star system at that time, which can help mitigate the impact of shareholding reduction; ② Analysts from private equity state that the sector of electronic components in which the company operates has seen a price increase exceeding that of Fevolite's stock prices since the beginning of the year. With the company's stock price being at a relatively low position, discounting the inquiry transfer of shares is relatively objective and reasonable.

cls.cnDec 4 09:01 ET

Naxinwei: Multiple cockpit field chips are planned for mass production and release next year, with acquisitions targeting the autos electronics and broader energy sectors | Directly covering the earnings conference.

Naxin Micro announced that it will focus on cabin area layout next year, expecting to mass produce and release multiple cabin area chips. Naxin Micro director and board secretary Jiang Chaoshang stated that the company's future investment and mergers will continue to focus on the main businesses of auto electronics and general energy tracks.

cls.cnDec 4 07:08 ET

Jingsheng Shares: The photovoltaic industry may see a turnaround in the first quarter of next year. 8-inch silicon carbide crystal growth equipment has been delivered to the market | Direct hit on the earnings conference

①Wu Chunsheng stated that the company's 8-inch silicon carbide long crystal growth equipment has been delivered to the market, which will continue to contribute to the company's revenue in the future; ②Li Hui introduced that the company has launched a super low oxygen overall solution to the market, with the oxygen content of silicon rods controllable below 5ppm.

cls.cnDec 4 07:00 ET

New China Life Insurance acquired a stake in haitong sec's H shares, marking the first time in five years that an insurance institution has taken a stake in a listed brokerage, and it is still buying shares after the acquisition.

① New China Life Insurance announced today that it has made a significant investment in Haitong Sec listed in Hong Kong, with the latest announcement showing a shareholding ratio of 5.4846%. ② According to data from the industry association, this is the first time this year that insurance funds have taken a stake in brokerage stocks. It is also the first time in five years that they have taken a stake in brokerage stocks. ③ The latest announcement from yesterday (December 3) shows that New China Asset is still continuing to buy, having acquired 8 million shares of Haitong Sec on December 2 at a price of 7.0024 HKD per share.

cls.cnDec 4 05:26 ET